CVR 26902398Public limited company (A/S)Engroshandel med medicinalvarer og sygeplejeartikler (464610)Vassingerødvej 9, 3540 LyngeFounded 6 Dec 2002
Compare withsimilar companiesanother companyits industry
MISSIONPHARMA A/S
The newest trades with a company on a side are on the latest property trades.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Cite as: MISSIONPHARMA A/S, https://dandex.ai/company/26902398/missionpharma. Source: Dandex, from CVR, read 22 Nov 2026.
Dandex is Danish Company Data. Connect it once and ask about MISSIONPHARMA A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Dandex has an MCP server at https://dandex.ai/mcp and a REST API at https://dandex.ai/api/v1.
Set up DandexEmployees
60
CVR, Aug 2026
-3 (-4.8%) over 12 months
Revenue
933.9M
DKK, group, annual report 2026
+28% on 2025
Result
+120.6M
DKK, group, annual report 2026
Equity
319.3M
DKK, group, annual report 2026
CFAO HEALTHCARE SAParty outside CVR, France, 100% of capital and votes
Operating company
Dandex estimate: 60 employees registered in 2026Jean-Marc Pierre René Lecciasince 24 Sep 2026
Edouard Marc Marie Favreausince 1 Sep 2026
Owners of 5% or more. CVR registers shares in bands, not exact figures.
Party outside CVR, France100% of capital and votessince 15 Dec 2023
CVR 29782792100% of capital and votesnotified 15 Dec 202320 Oct 2006 to 15 Dec 2023
CVR 2746380050% to under 66.7% of capital and votes1 Dec 2003 to 28 May 2017
1 Danish company.
SubsidiaryCVR 19056007100% of capital and votes
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR. Subsidiary (datterselskab): 50% or more of the votes, a Dandex estimate; in the 50% band a joint venture is not ruled out.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Aug 2026, monthly: 60 employees, 57 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Q4 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | Q1 2010 | Q2 2010 | Q3 2010 | Q4 2010 | 2011 | 2012 | 2013 | 2014 | Jan 2015 | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | No count | 71 | 77 | 54 | 51 | 50 | 44 | 48 | No count | No count | No count | No count | 52 | 51 | 38 | 49 | 50 | 49 | 49 | 55 | 50 | 50 | 51 | 49 | 50 | 50 | 51 | 54 | 55 | 56 | 54 | 58 | 55 | 59 | 56 | 58 | 61 | 61 | 63 | 64 | 61 | 60 | 62 | 65 | 62 | 62 | 64 | 62 | 60 | 59 | 59 | 61 | 61 | 58 | 60 | 61 | 64 | 62 | 61 | 63 | 60 | 62 | 62 | 64 | 64 | 63 | 60 | 60 | 61 | 61 | 59 | 62 | 58 | 60 | 60 | 59 | 57 | 58 | 57 | 57 | 59 | 64 | 59 | 59 | 57 | 56 | 58 | 57 | 57 | 55 | 52 | 53 | 60 | 63 | 55 | 57 | 54 | 54 | 55 | 58 | 52 | 52 | 54 | 53 | 53 | 58 | 68 | 58 | 60 | 60 | 60 | 62 | 60 | 61 | 60 | 61 | 60 | 63 | 68 | 65 | 63 | 61 | 61 | 61 | 61 | 61 | 61 | 63 | 62 | 61 | 66 | 62 | 64 | 65 | 66 | 65 | 64 | 63 | 64 | 64 | 63 | 64 | 67 | 63 | 63 | 63 | 61 | 62 | 62 | 62 | 65 | 63 | 62 | 63 | 67 | 60 |
| FTE | 0 | 70 | 74 | 59 | 50 | 48 | 44 | 48 | 49 | 48 | 50 | 46 | 48 | 51 | 44 | 44 | 49 | 48 | 48 | 51 | 49 | 48 | 50 | 48 | 49 | 49 | 50 | 51 | 52 | 52 | 53 | 55 | 54 | 56 | 55 | 56 | 59 | 60 | 62 | 61 | 60 | 59 | 61 | 63 | 61 | 59 | 62 | 61 | 59 | 58 | 58 | 59 | 59 | 56 | 58 | 59 | 61 | 58 | 59 | 60 | 58 | 60 | 60 | 62 | 61 | 58 | 58 | 57 | 58 | 57 | 56 | 60 | 56 | 54 | 57 | 56 | 55 | 56 | 55 | 56 | 58 | 60 | 56 | 57 | 55 | 54 | 56 | 55 | 55 | 53 | 50 | 52 | 53 | 60 | 53 | 54 | 52 | 52 | 53 | 53 | 49 | 50 | 51 | 51 | 51 | 54 | 60 | 56 | 56 | 57 | 58 | 57 | 58 | 59 | 57 | 59 | 57 | 57 | 64 | 61 | 61 | 59 | 59 | 59 | 58 | 59 | 59 | 60 | 60 | 59 | 63 | 59 | 59 | 60 | 61 | 61 | 58 | 59 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 59 | 58 | 59 | 59 | 60 | 63 | 61 | 61 | 60 | 63 | 57 |
| Series | Quarterly | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Quarterly | Quarterly | Quarterly | Quarterly | Annual | Annual | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group. CVR changed its monthly method in Oct 2019: a step there need not be real.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
Group figures (koncern) for 2023 to 2026, the company's own for 2022, in DKK, from the annual reports filed in XBRL.
2026, DKK: Revenue 933.9M, Gross profit 234.7M, Operating profit 158.7M, Result for the year 120.6M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2026, DKK: Total assets 457.4M, Equity 319.3M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2022 | 2023group | 2024group | 2025group | 2026group |
|---|---|---|---|---|---|
| Revenue | 693,959 | 942,492 | 928,798 | 729,797 | 933,912 |
| Gross profit | 122,255 | Not reported | 219,958 | 162,425 | 234,671 |
| Operating profit | +71,631 | +156,364 | +151,336 | +92,485 | +158,733 |
| Result for the year | +57,982 | +119,159 | +119,746 | +73,302 | +120,601 |
| Equity | 312,809 | 340,843 | 320,520 | 274,207 | 319,309 |
| Total assets | 428,519 | 538,204 | 470,294 | 408,988 | 457,350 |
| Employees (average) | 55 | 58 | 158 | 169 | 170 |
Annual report 2026
1 Apr 2025 to 31 Mar 2026, published 28 Jun 2026
Annual report 2025
1 Apr 2024 to 31 Mar 2025, published 1 Jul 2025
Annual report 2024
1 Apr 2023 to 31 Mar 2024, published 1 Jul 2024
Annual report 2023
1 Apr 2022 to 31 Mar 2023, published 6 Jul 2023
Annual report 2022
1 Apr 2021 to 31 Mar 2022, published 8 Jul 2022
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseMergerPaid in 4,437,970 | None | 4,437,970 | None | 2,100,000 | |
| IncreaseMergerPaid in 4,447,030 | None | 4,447,030 | None | 2,050,000 | |
| IncreaseMergerPaid in 58,747,500 | None | 58,747,500 | None | 2,000,000 | |
| FoundingNot read from the announcement | None | None | None | 1,000,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
Group figures (koncern) for 2023 to 2026, the company's own for 2022, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2022 | 2023group | 2024group | 2025group | 2026group |
|---|---|---|---|---|---|
| Revenue growth (omsætningsvækst) | -5.1% | 35.8% | 0.5% | -21.4% | 28% |
| EBIT margin (overskudsgrad) | 10.3% | 16.6% | 16.3% | 12.7% | 17% |
| EBITDA | 73,221 | 157,914 | 154,265 | 95,776 | 163,253 |
| EBITDA margin (EBITDA-margin) | 10.5% | 16.8% | 16.6% | 13.1% | 17.5% |
| Employee growth (vækst i antal ansatte) | -5.2% | 5.5% | 5.3% | 7% | 0.6% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 542note 1 | Not reportednote 2 | 6,856 | 14,841 | 2,165 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
How each credit metric is calculated:
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Source: CVR, read 22 Nov 2026.
45 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Vedtægter ændret: 20.10.2026
Selskabet tegnes af en direktør i forening med et bestyrelsesmedlem, eller af to bestyrelsesmedlemmer i forening, eller af to direktører i forening, eller af den samlede bestyrelse.
Bestyrelse:
Fratrådte:
Eric Pierre Jean Muris, den 24.09.2026, Jean-Marc Pierre René Leccia, (formand), den 24.09.2026.
Tiltrådte:
Eric Pierre Jean Muris, (formand), den 24.09.2026, Jean-Marc Pierre René Leccia, den 24.09.2026.
Direktion:
Fratrådte:
Nicolai Buhl Andersen, (adm. dir), den 24.09.2026.
Tiltrådte:
Jean-Marc Pierre René Leccia, (adm. dir), den 24.09.2026.
Direktion:
Fratrådte:
Christian Monrad Overgaard, (adm. dir), den 01.09.2026.
Tiltrådte:
Nicolai Buhl Andersen, (adm. dir), den 01.09.2026, Edouard Marc Marie Favreau, den 01.09.2026.
Direktion:
Fratrådte:
Alexandre Pierre Jean Vialatte, den 15.06.2026.
Til Erhvervsstyrelsens registrering om fusion, registreret den 11.01.2024 meddeles det at kapitalen rettelig er:
Kapitalforhøjelsen er besluttet den 15.12.2023.
kr. 50.000,00, indbetalt ved fusion, kurs 8.875,94.
Kapitalen udgør herefter kr. 2.100.000,00.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion.
Virksomheden er fusioneret med CVR-nummer: 29782792 MISSIONPHARMA GROUP ApS, der samtidigt er opløst.
Vedtægter ændret: 15.12.2023
Nye binavne: Missionpharma Group A/S, P. Ginnerup A/S
Kapitalforhøjelsen er besluttet den 15.12.2023.
kr. 50.000,00, indbetalt ved fusion, kurs 8.875,94.
Kapitalen udgør herefter kr. 2.050.000,00.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion.
Virksomheden er fusioneret med CVR-nummer: 33956509 GIN INVEST I ApS, der samtidigt er opløst.
Vedtægter ændret: 15.12.2023
Nyt binavn: Gin Invest I A/S
Kapitalforhøjelsen er besluttet den 15.12.2023.
kr. 50.000,00, indbetalt ved fusion, kurs 8.894,06.
Kapitalen udgør herefter kr. 2.050.000,00.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 26902398 MISSIONPHARMA A/S (fortsættende), der tillige driver virksomhed under navnene MISSIONPHARMA INTERNATIONAL PROJECT SERVICES A/S, MISSIONPHARMA INTERNATIONAL RELIEF SERVICES A/S, MISSIONPHARMA INTERNATIONAL A/S, INTERNATIONAL PROJECT SERVICES A/S, Missionpharma Properties A/S, Missionpharma Ejendomme A/S og CVR-nummer: 29782792 MISSIONPHARMA GROUP ApS (ophørende), der tillige driver virksomhed under navnene P. Ginnerup ApS.
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 26902398 MISSIONPHARMA A/S og CVR-nummer: 29782792 MISSIONPHARMA GROUP ApS må antages at være tilstrækkeligt sikrede efter fusionen.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 26902398 MISSIONPHARMA A/S (fortsættende), der tillige driver virksomhed under navnene MISSIONPHARMA INTERNATIONAL PROJECT SERVICES A/S, MISSIONPHARMA INTERNATIONAL RELIEF SERVICES A/S, MISSIONPHARMA INTERNATIONAL A/S, INTERNATIONAL PROJECT SERVICES A/S, Missionpharma Properties A/S, Missionpharma Ejendomme A/S og CVR-nummer: 33956509 GIN INVEST I ApS (ophørende).
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 26902398 MISSIONPHARMA A/S og CVR-nummer: 33956509 GIN INVEST I ApS må antages at være tilstrækkeligt sikrede efter fusionen.
Bestyrelse:
Fratrådte:
Aymeric Erouart, den 01.02.2023.
Revision:
Fratrådte:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 29.06.2022.
Tiltrådte:
CVR-NR. 31061741 MAZARS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Midtermolen 1, 2. tv, 2100 København Ø, den 29.06.2022.
Direktion:
Fratrådte:
Poul Lindof, den 30.11.2021.
Bestyrelse:
Fratrådte:
Annie Renée Simonne Dateu, den 03.12.2020.
Tiltrådte:
Patricia Hec, den 03.12.2020.
Vedtægter ændret: 13.02.2019
Bestyrelse:
Fratrådte:
Kim Erik Ginnerup, den 13.02.2019.
Tiltrådte:
Kim Erik Ginnerup, (næstformand), den 13.02.2019, Annie Renée Simonne Dateu, den 13.02.2019, Aymeric Erouart, den 13.02.2019.
Selskabet tegnes af to bestyrelsesmedlemmer i forening, eller af to direktører i forening, eller af den samledebestyrelse.
Direktion:
Fratrådte:
Kim Erik Ginnerup (adm. dir), den 30.08.2018.
Tiltrådte:
Christian Monrad Overgaard (adm. dir), den 30.08.2018.
Vedtægter ændret: 06.12.2017
Regnskabsår ændret til: 01.04 - 31.03
Omlægningsperiode: 01.01.2018 - 31.03.2018
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion.
Virksomheden er fusioneret med CVR-nummer: 57175516 MISSIONPHARMA PROPERTIES A/S, der samtidigt er opløst.
Vedtægter ændret: 29.05.2017
Nye binavne: Missionpharma Properties A/S, Missionpharma Ejendomme A/S
Kapitalforhøjelsen er besluttet den 29.05.2017.
kr. 1.000.000,00, indbetalt ved fusion, kurs 5.874,75.
Kapitalen udgør herefter kr. 2.000.000,00.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 26902398 MISSIONPHARMA A/S (fortsættende), der tillige driver virksomhed under navnene MISSIONPHARMA INTERNATIONAL PROJECT SERVICES A/S, MISSIONPHARMA INTERNATIONAL RELIEF SERVICES A/S, MISSIONPHARMA INTERNATIONAL A/S, INTERNATIONAL PROJECT SERVICES A/S og CVR-nummer: 57175516 MISSIONPHARMA PROPERTIES A/S (ophørende), der tillige driver virksomhed under navnene MISSIONPHARMA EJENDOMME A/S.
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 26902398 MISSIONPHARMA A/S og CVR-nummer: 57175516 MISSIONPHARMA PROPERTIES A/S må antages at være tilstrækkeligt sikrede efter fusionen.
CVR-nummer
26902398.
NAVN:
MISSIONPHARMA A/S.
Adresse: Vassingerødvej 9, 3540 Lynge.
Kommune: Allerød.
Revision:
Fratrådte:
KPMG STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 20.04.2015.
Tiltrådte:
CVR-NR. 33771231 PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Strandvejen 44, 2900 Hellerup, den 20.04.2015.
Direktion:
Udtrådt af direktionen:
Mikkel Mørkedal Wakefield, den 15.03.2013.
Indtrådt i direktionen:
Direktør Kim Erik Ginnerup (adm. dir), den 15.03.2013.
Direktion:
Tiltrådt som adm. dir: Mikkel Mørkedal Wakefield, den 30.11.2012.
Vedtægter ændret:
20.11.2012.
Revision:
Udtrådt af revisionen:
CVR-NR. 26052394 ERNST & YOUNG P/S, den 20.11.2012.
Indtrådt i revisionen:
CVR-NR. 30700228 KPMG STATSAUTORISERET REVISIONSPARTNERSELSKAB, Osvald Helmuths Vej 4, postboks 250, 2000 Frederiksberg, den 20.11.2012.
Regnskabsår ændret til:
01.01 - 31.12.
Omlægningsperiode:
01.05.2012 - 31.12.2012.
Vedtægter ændret:
01.11.2012.
Bestyrelse:
Tiltrådt som formand:
Jean-Marc Pierre René Leccia, den 01.11.2012, Tiltrådt som næstformand: Denis Georges Fernand Maurice, den 01.11.2012, Fratrådt som formand, men forbliver i bestyrelsen: Kim Erik Ginnerup, den 01.11.2012.
Selskabets tegnes af to bestyrelsesmedlemmer i forening, af tre direktører i forening, af næstformanden for bestyrelsen i forening med en direktør eller af den samlede bestyrelse.
Vedtægter ændret:
18.07.2012.
Bestyrelse:
Udtrådt af bestyrelsen:
Jesper Funding Andersen, den 18.07.2012, Paule Georgette Ginnerup, den 18.07.2012, Leif Ole Lund-Andersen, den 18.07.2012, Peter Normann, den 18.07.2012.
Indtrådt i bestyrelsen:
Jean-Marc Pierre René Leccia, den 18.07.2012, Denis Georges Fernand Maurice, den 18.07.2012, Eric Pierre Jean Muris, den 18.07.2012.
Selskabet tegnes af to bestyrelsesmedlemmer i forening, af to direktører i forening eller af den samlede bestyrelse.
Bestyrelse:
Udtrådt af bestyrelsen:
Leif Ole Lund-Andersen, den 15.12.2010.
Indtrådt i bestyrelsen:
Direktør Kim Erik Ginnerup (formand), den 15.12.2010.
Direktion:
Udtrådt af direktionen:
Kim Erik Ginnerup, den 15.12.2010.
Vedtægter ændret:
27.09.2010.
Direktion:
Udtrådt af direktionen:
Christian Ilsøe, den 04.01.2010.
Indtrådt i direktionen:
Direktør Poul Lindof (Økonomidirektør), den 04.01.2010.
Direktion:
Indtrådt i direktionen:
Økonomidirektør (CFO) Christian Ilsøe (Økonomidirektør), den 15.09.2008, Chief Operating Officer (COO) Mikkel Mørkedal Wakefield, den 15.09.2008.
Vedtægter ændret:
31.08.2004.
Selskabet tegnes af en direktør i forening med et bestyrelsesmedlem, af to bestyrelsesmedlemmer i forening eller af to direktører i forening.
Bestyrelse:
Udtrådt af bestyrelsen:
Kim Erik Ginnerup, den 18.08.2004, Erik Schou Stavnstrup, den 18.08.2004.
Indtrådt i bestyrelsen:
Direktør Henning Brømsøe Termansen, den 18.08.2004.
Vedtægter ændret:
11.12.2002.
Nye binavne:
MISSIONPHARMA INTERNATIONAL PROJECT SERVICES A/S (MISSIONPHARMA A/S), MISSIONPHARMA INTERNATIONAL RELIEF SERVICES A/S (MISSIONPHARMA A/S), MISSIONPHARMA INTERNATIONAL A/S (MISSIONPHARMA A/S), INTERNATIONAL PROJECT SERVICES A/S (MISSIONPHARMA A/S).
Stiftelsesdato:
06.12.2002.
Seneste vedtægtsdato:
06.12.2002.
Kapital:
kr. 1.000.000,00.
Indbetalingsmåde:
i værdier kr. 1.000.000,00 til kurs 4.415,02.
Stifter:
CVR-NR. 16929484 MISSIONPHARMA INTERNATIONAL PROJECT SERVICES A/S, Vassingerødvej 9, 3540 Lynge, den 06.12.2002.
Bestyrelse:
Advokat Leif Ole Lund-Andersen (formand), den 06.12.2002, Senior Vice President Jesper Funding Andersen, den 06.12.2002, Alan Per Binau, den 06.12.2002, Direktør Kim Erik Ginnerup, den 06.12.2002, Direktør Paule Georgette Ginnerup, den 06.12.2002, Direktør Erik Schou Stavnstrup, den 06.12.2002.
Direktion:
Direktør Kim Erik Ginnerup, den 06.12.2002, Direktør Erik Schou Stavnstrup, den 06.12.2002.
Selskabet tegnes af en direktør i forening med et bestyrelsesmedlem eller to bestyrelsesmedlemmer i forening.
Revision:
CVR-NR. 44682915 REVISIONSFIRMAET NIELS HARDER STATSAUTORISERET REVISOR A/S, Rådmandsgade 45, 2200 København N, den 06.12.2002.
Første regnskabsår:
01.05.2002 - 30.04.2003.
Regnskabsår:
01.05 - 30.04.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 22 Nov 2026.
What Pro holds for MISSIONPHARMA A/S:
Have Pro? Sign in.
P-number 1001186595Vassingerødvej 9, 3540 Lynge
P-number 1009571600Vassingerødvej 9, 3540 Lynge
No other current company drawn.
No other current company drawn.
No other current company drawn.